Chemotherapy News and Research

Latest Chemotherapy News and Research

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.

1 Jun 2012

Viewpoints: Bishops' request for contraception exemption may push legal precedent; Maine's experiment on health care

43 Roman Catholic organizations have filed lawsuits challenging a ... regulation that requires employers or their health insurers to offer birth control coverage to workers. The plaintiffs say that complying with the regulation would violate their religious freedom.

1 Jun 2012

NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute's Adult Brain Tumor Consortium (ABTC) using the company's first product candidate mibefradil.

1 Jun 2012

Data from Response Genetics' tests against cancer to be presented at ASCO 2012

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.

31 May 2012

CTI announces results from PIX301 phase 3 trial of Pixuvri for NHL

Cell Therapeutics, Inc. today announced that results from its PIX301 phase 3 clinical trial of Pixuvri (pixantrone) have been published online in The Lancet Oncology.

31 May 2012

TAU researcher develops new antibodies to target and destroy cancer cells

Because cancer cells grow very quickly, chemotherapy is designed to target cells whose numbers grow rapidly. But this treatment comes with a heavy price - many healthy cells essential for body functions are also targeted and killed by the toxin. This dangerous side-effect has prompted researchers to seek better and more selective ways to kill cancer cells inside the body.

31 May 2012

Experimental drug shows promise for elderly chronic leukemia patients

The experimental drug ibrutinib is highly active and well tolerated in elderly, treatment-naive patients with chronic lymphocytic leukemia, US researchers report.

30 May 2012

Beyond chemotherapy to cure leukemia

The fight against cancer is not won in a single battle: long after a cancer has been beaten into remission, it can return. The reason for this is under debate, and much is unclear.

30 May 2012

Scientists show why leukemia often returns

The fight against cancer is not won in a single battle: Long after a cancer has been beaten into remission, it can return. The reason for this is under debate, and much is unclear. New research led by Weizmann Institute scientists shows that, at least for one type of blood cancer, the source of cancer recurrence is in a set of cells that do not proliferate as quickly as regular cancer cells, and thus able to survive chemotherapy.

30 May 2012

Marshall Edwards initiates ME-344 Phase I trial in solid tumors

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors.

30 May 2012

Scientists develop synthetic peptide that overcomes cancer cells’ survival defenses

Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.

30 May 2012

Secreted vesicles play role in spread of cancer

Cancer researchers have known for well over a century that different tumor types spread only to specific, preferred organs. But no one has been able to determine the mechanisms of organ specific metastasis, the so-called "soil and seed" theory of 1889. New details that could help shed light on this hypothesis have been provided by a team of researchers from Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, and their collaborators, proposing a new mechanism controlling cancer metastasis that offers fresh diagnostic and treatment potential.

29 May 2012

Lung in Oncology models for drug discovery launched by PRECOS

Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, has launched its Lung In ONcology model atlas (LION).

29 May 2012

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 trial for cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment in Lm-LLO-E7-15, the 110 patient, randomized Phase 2 trial of ADXS-HPV in women with recurrent/refractory cervical cancer who have failed cytotoxic therapy.

29 May 2012

Health Robotics announces HAT as new marketing and service channel in Saudi Arabia

Health Robotics today announced a new marketing and service channel for its world-leading i.v.STATION ONCO, i.v.SOFT, and i.v.STATION products with Kingdom of Saudi Arabia-based market leader Hospital Automation Technology (HAT). Health Robotics continues to spearhead the global healthcare industry and persisting on its worldwide quest to provide safe and cost-effective Intravenous Admixture Compounding Automation all over the world.

28 May 2012

Positive results from Acacia Phase II APD421 study in prevention of post-operative nausea & vomiting

Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV).

28 May 2012

Giant cells protect fungus Cryptococcus neoformans during infection

Giant cells called "titan cells" protect the fungus Cryptococcus neoformans during infection, according to two University of Minnesota researchers. Kirsten Nielsen, Ph.D., an assistant professor in the department of microbiology, and recent Ph.D. recipient Laura Okagaki believe their discovery could help develop new ways to fight infections caused by Cryptococcus.

28 May 2012

Blocking Skp2 protein might inhibit glycolysis and treat breast cancer

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

28 May 2012

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

City of Hope was granted a $5,217,004 early translational research award by the California Institute for Regenerative Medicine (CIRM) to support the development of a T cell-based immunotherapy that re-directs a patient's own immune response against glioma stem cells.

28 May 2012

FDA reauthorization bill sails through Senate

Showing unusual bipartisan spirit, the Senate passed a massive FDA user-fee reauthorization bill Thursday designed to prevent drug shortages and speed federal approval of medicines, including lower-cost generic versions.

25 May 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

Viewpoints: Bishops' request for contraception exemption may push legal precedent; Maine's experiment on health care

NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial

Data from Response Genetics' tests against cancer to be presented at ASCO 2012

CTI announces results from PIX301 phase 3 trial of Pixuvri for NHL

TAU researcher develops new antibodies to target and destroy cancer cells

Experimental drug shows promise for elderly chronic leukemia patients

Beyond chemotherapy to cure leukemia

Scientists show why leukemia often returns

Marshall Edwards initiates ME-344 Phase I trial in solid tumors

Scientists develop synthetic peptide that overcomes cancer cells’ survival defenses

Secreted vesicles play role in spread of cancer

Lung in Oncology models for drug discovery launched by PRECOS

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 trial for cervical cancer

Health Robotics announces HAT as new marketing and service channel in Saudi Arabia

Positive results from Acacia Phase II APD421 study in prevention of post-operative nausea & vomiting

Giant cells protect fungus Cryptococcus neoformans during infection

Blocking Skp2 protein might inhibit glycolysis and treat breast cancer

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

FDA reauthorization bill sails through Senate

Cancer Research - Second Edition eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in